-- The global epilepsy drugs market analyst says a trend which will boost market growth is the reformulation of marketed drugs. Drug delivery systems such as dispersible and film-coated tablets increase the efficacy of medicines either by increasing the bioavailability of the drug or by expanding patient compliance. This reformulation results in products with improved safety and efficacy profiles and provides an opportunity for drug manufacturers to extend the term of their drug's patents, delaying the market entry of generics. For instance, UCB, Pfizer, and GSK developed film-coated tablets of Keppra, Neurontin, and Trobalt, respectively. Film-coated tablets offer specific properties such as taste-masking, moisture and light protection, superior product appearance, and mechanical resistance.
Complete report on epilepsy drugs market spread across 87 pages, analyzing 4 major companies and providing 49 data exhibits is now available at http://www.rnrmarketresearch.com/global-epilepsy-drugs-market-2016-2020-market-report.html
The epilepsy drugs market growth can be accredited to the development of novel therapeutics using innovative technologies. Several technological advancements in the field of epilepsy drugs are resulting in the development of novel molecules. For instance, Aprecia Pharmaceuticals develops Spritam (levetiracetam) using the ZipDose technology, which uses a three-dimensional printing (3DP) platform. During 2015, the Americas dominated the global epilepsy drugs market by accounting for almost 51% of the overall market space. The high prevalence of the disorder and the treatment options in the region coupled with collaborations among local vendors is expected to boost growth in the epilepsy drugs market in the Americas during the forecast period.
According to the epilepsy drugs market report, a key growth driver is the tentative approval of late-stage pipeline molecules. Though a number of branded and generic drugs are available in the market to treat epilepsy, they provide only symptomatic treatment. Hence, the need for effective medications still prevails in the market. This has increased investment in the R&D of new drugs for epilepsy by companies such as Marinus Pharmaceuticals, SAGE Therapeutics, H. Lundbeck, and CURx Pharmaceuticals. Drugs in the regulatory filing and Phase III stages are expected to enter the market during the forecast period. Order a copy of Global Epilepsy Drugs Market 2016-2020 report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=631331
The broad-spectrum anti-epileptic drugs segment was the primary revenue generator in the global epilepsy drugs market in 2015 with a market share of around 48%. Broad-spectrum anti-epileptic drugs treat both partial and generalized seizures. These drugs include levetiracetam, lamotrigine, phenytoin, topiramate, felbamate, zonisamide, valproic acid, and phenobarbital.
The following companies are the key players in the global epilepsy drugs market: Eisai, GSK, Pfizer, and UCB. Other prominent vendors in the epilepsy drugs market are: Acorda Therapeutics, Alexza Pharmaceuticals, Aprecia Pharmaceuticals, Aurobindo Pharma, Biscayne Pharmaceuticals, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, D-Pharm, F. Hoffmann-La Roche, Grupo Ferrer Internacional, GW Pharmaceuticals, Insero Health, INSYS Therapeutics, Janssen Pharmaceuticals, Ligand Pharmaceuticals, H. Lundbeck, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda, Neurelis, Nobelpharma, Novartis, Orphelia Pharma, SAGE Therapeutics, SciFlour, Sedpr Pharmaceuticals, Shire, SK Biopharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals (US), Supernus Pharmaceuticals, Takeda, Turing Pharmaceuticals, Upsher-Smith, Valeant Pharmaceuticals, and Zogenix.
Another related report is Global Migraine Drugs Market 2016-2020, the analysts forecast global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020. A key market driver is the unmet needs of migraine sufferers around the world. Prophylactic therapy with improved efficacy and tolerability is one of the most significant unmet needs in individuals suffering from migraine. The US Agency for Healthcare Research and Quality estimated that only about 12% of the adults with migraines take preventive medications. Browse complete report @ http://www.rnrmarketresearch.com/global-migraine-drugs-market-2016-2020-market-report.html
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: RnRMarketResearch
Phone: + 1 888 391 5441
Website: http://www.rnrmarketresearch.com/global-epilepsy-drugs-market-2016-2020-market-report.html
Release ID: 123244
Google
RSS